Login to Your Account



NEWCO NEWS

HONG KONG – With $13.2 million in new financing, Tokyo-based oncology drug developer Anaeropharma Science Inc. now plans to focus on research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium.

HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.

SHANGHAI – Inventisbio Inc., has emerged from stealth, nabbing $19 million in series B financing from health care venture financiers Orbimed and Lilly Asia Ventures (LAV).

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: